Pharmaceutical Executive July 28, 2025
Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types.
Dr. Ben Zeskind, CEO and co-founder of Immuneering, spoke with Pharmaceutical Executive about his company’s approach to treating cancer. Based on the company’s research, he believes that treating tumors at a slower and steadier pace may produce more reliable results that also avoid subjecting patients to some of the worst side effects that often accompany cancer treatment.
Pharmaceutical Executive: Can you discuss the history of Immuneering?
Dr. Ben Zeskind: We started the company 17 years ago with the goal of helping cancer patients live longer and longer until they eventually outlive their disease. We can transform cancer into something that’s more of a manageable condition, like HIV,...
Today's Sponsors
Today's Sponsor